

[204] FROM CODE TO CURE: PREDICTIVE DISCOVERY OF NOVEL IMMUNE CHECKPOINTS

Emmanuel Weyl¹, ¹ Compugen

- **Investment Rational**

Immunotherapy is the most promising field in cancer therapy leading to the approval of multiple anti-PD-1 antibodies. Compugen has discovered several novel immune checkpoint candidates with the potential to develop first-in-class biologics against them. This differentiates us from the many companies in this field pursuing known targets and can potentially benefit unresponsive patient populations and indications.

- **Business Strategy**

Compugen's business model is based on selectively entering collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements.

The company has an ongoing collaboration with Bayer Pharma surrounding two immune checkpoint programs and to date has received \$25.4 million out of over \$540 million in milestone payments.

- **Core Technology**

Compugen discovers novel drug targets through a predictive, computational process that combines human biology derived from genome analysis, with disease information derived from analysis of vast amounts of proprietary and public data. This process is applicable to many fields of medical interest and usually results in multiple drug target candidates, which are often difficult to identify using traditional approaches.

- **Product Profile/Pipeline**

Compugen's pipeline consists of early and late preclinical stage immuno-oncology programs based on novel targets discovered internally, primarily immune checkpoint and myeloid candidates. Additionally, our pipeline currently includes a preclinical fusion protein candidate, CGEN-15001, which in pre-clinical models has demonstrated the potential for restoration of immune tolerance and rebalancing homeostasis in autoimmune diseases.

- **What's Next?**

Compugen plans to advance its lead immuno-oncology program, COM701, towards clinical testing with an IND filing planned in Q4 2017.

Additionally, the company has selected COM902 as the lead clinical antibody for its CGEN-15137/TIGIT program. Pre-clinical studies support the clinical rationale for the combination of COM701 and COM902, in addition to monotherapy use, as immunotherapies to treat various cancer types.